Given a pathogenic role of IL-18 in AOSD, blocking IL-18 with recombinant IL18 BP (tadekinig alfa) has therapeutic efficacy for AOSD patients in a phase II clinical trial47. This evidence concerns the gene IL18 and adult-onset Still disease.